Literature DB >> 15521000

An analysis of the potential impact of computed tomographic colonography (virtual colonoscopy) on colonoscopy demand.

Chin Hur1, G Scott Gazelle, Michael E Zalis, Daniel K Podolsky.   

Abstract

BACKGROUND AND AIMS: There has been much speculation about the potential impact on the use of conventional colonoscopy if "virtual" computed tomographic colonography (CTC) became a widely accepted modality for colorectal cancer (CRC) screening. However, no formal analysis of the impact of CTC on colonoscopy demand has been reported.
METHODS: A mathematical model to predict colonoscopy demand based on several relevant input parameters was constructed. Current national colonoscopy practice, estimated using various published reports, was used as the foundation to project colonoscopy demand if CTC were implemented as the primary CRC screening modality.
RESULTS: In the base-case analysis, if CTC were used as the primary modality for CRC screening, 1.78 million colonoscopies could be eliminated from the total 6.47 million in 2003. Depending on the polyp size threshold used to define a CTC study as positive (6 or 10 mm), this loss would be partially offset by 1.21 million (6 mm) or .34 million (10 mm) follow-up colonoscopies for CTC examinations with positive findings, resulting in a net loss of .57 million (8.8% decrease) (6 mm) or 1.44 million (22.3% decrease) (10 mm). Extensive sensitivity analyses showed that the findings of this model were robust and insensitive to most parameters tested but were sensitive to a few parameters, including the percentage of CTC examinations with positive findings.
CONCLUSIONS: Wide-scale implementation of CTC for CRC screening would likely lead to a decrease in use of conventional colonoscopy. The percentage of CTC studies with positive findings seemed to be a pivotal variable, which would be determined in large part by the polyp size ultimately established to define a positive finding.

Entities:  

Mesh:

Year:  2004        PMID: 15521000     DOI: 10.1053/j.gastro.2004.07.018

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  CT Colonography: Impact of Recent Findings on the Future Practice of Colorectal Cancer Screening.

Authors:  Joel V Brill
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-11

Review 2.  Current status of CT colonography.

Authors:  Suzanne M Frentz; Ronald M Summers
Journal:  Acad Radiol       Date:  2006-12       Impact factor: 3.173

Review 3.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 4.  [Early diagnosis of colorectal tumors].

Authors:  C Lamberti; T Sauerbruch
Journal:  Internist (Berl)       Date:  2005-04       Impact factor: 0.743

Review 5.  Computed tomographic colonography: hope or hype?

Authors:  Otto Schiueh-Tzang Lin
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

6.  CT colonography: Friend or foe of practicing endoscopists.

Authors:  Stacy B Menees; Ruth Carlos; James Scheiman; Grace H Elta; A Mark Fendrick
Journal:  World J Gastrointest Endosc       Date:  2009-10-15

7.  Optical colonoscopy and virtual colonoscopy numbers after initiation of a CT colonography program: long term data.

Authors:  Mark Benson; Jeff Pier; Sally Kraft; David Kim; Perry Pickhardt; Jennifer Weiss; Deepak Gopal; Mark Reichelderfer; Patrick Pfau
Journal:  J Gastrointestin Liver Dis       Date:  2012-12       Impact factor: 2.008

8.  Variation of agreement in polyp size measurement between computed tomographic colonography and pathology assessment: clinical implications.

Authors:  Samir Gupta; Valerie Durkalski; Peter Cotton; Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02       Impact factor: 11.382

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.